COVID-19 Study of Pharmacokinetics, Safety, Tolerability, and Efficacy of Intravenous Anti-Spike(s) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) for the Treatment of Pediatric Patients Hospitalized Due to COVID-19
Stopped early · Phase 1
Conditions studied: COVID-19
In brief
The primary objectives of the study are: * To characterize the concentrations of casirivimab+imdevimab in serum over time * To evaluate the safety and tolerability of casirivimab+imdevimab The secondary objective of the study is: • To assess the immunogenicity of casirivimab+imdevimab
Key facts
- Study ID
- NCT05092581
- Run by
- Regeneron Pharmaceuticals
- People needed
- 2
- Starts
- 2021-12-16
- Expected to finish
- 2022-06-09
- Last updated by the study team
- 2025-10-14
Who can join
Age: any, up to 17. Sex: any. Healthy volunteers: not accepted.
Where it is running
- State University of New York at Stony Brook — Stony Brook, New York, United States
- Le Bonheur Children's Hospital — Memphis, Tennessee, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.